Cord blood–derived mesenchymal stem cell: hope for recessive dystrophic epidermolysis bullosa patients!

 | Post date: 2021/11/11 | 
Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease that causes severe mucocutaneous fragility due to mutations in COL7A1 (encoding type VII collagen [C7]). the results of the first phase I/II clinical trial of intravenous administrations of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in patients with RDEB indicate that intravenous hUCB-MSC infusions were well tolerated, without serious adverse events. Improvements in the Birmingham Epidermolysis Bullosa Severity Score, body surface area involvement, blister counts, pain, pruritus, and quality of life were observed with maximal effects at 56–112 days after treatment. hUCB-MSC administration induced M2 macrophage polarization and reduced mast cell infiltration in RDEB skin. Serum levels of substance P were decreased after therapy.
Read more 



CAPTCHA

View: 54 Time(s)   |   Print: 5 Time(s)   |   Email: 0 Time(s)   |   0 Comment(s)


© 2021 CC BY-NC 4.0 | Modern Medical Laboratory Journal